Cargando…
A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.
Patients with breast cancer treated with MPA often report an improvement in appetite. Similar appetite stimulation is seen in patients treated with some corticosteroids, but MPA has a potential advantage over these drugs in that it does not exert a catabolic effect. MPA (100 mg tds orally) has there...
Autores principales: | Downer, S., Joel, S., Allbright, A., Plant, H., Stubbs, L., Talbot, D., Slevin, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968469/ https://www.ncbi.nlm.nih.gov/pubmed/8494706 |
Ejemplares similares
-
Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
por: Malik, S. T., et al.
Publicado: (1991) -
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
por: Johnson, J. R., et al.
Publicado: (1984) -
Medroxyprogesterone Acetate (MPA) Enhances HIV-1 Accumulation and Release in Primary Cervical Epithelial Cells by Inhibiting Lysosomal Activity
por: Jia, Xiangxu, et al.
Publicado: (2021) -
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016) -
Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)